Equities research analysts forecast that Sientra Inc (NASDAQ:SIEN) will report sales of $19.03 million for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Sientra’s earnings, with the lowest sales estimate coming in at $18.80 million and the highest estimate coming in at $19.30 million. Sientra posted sales of $17.55 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 8.4%. The business is expected to report its next earnings report on Tuesday, August 6th.

On average, analysts expect that Sientra will report full year sales of $80.87 million for the current year, with estimates ranging from $80.80 million to $81.00 million. For the next financial year, analysts expect that the company will report sales of $105.18 million, with estimates ranging from $99.40 million to $110.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Sientra.

Sientra (NASDAQ:SIEN) last released its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.76) by ($0.15). Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%. The firm had revenue of $17.55 million during the quarter, compared to analysts’ expectations of $17.00 million.

A number of research firms have issued reports on SIEN. Zacks Investment Research downgraded Sientra from a “hold” rating to a “sell” rating in a research report on Friday, April 5th. Wells Fargo & Co started coverage on Sientra in a research report on Thursday, March 14th. They issued a “market perform” rating and a $9.00 price target for the company. ValuEngine cut Sientra from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. Maxim Group reiterated a “buy” rating and issued a $20.00 price target on shares of Sientra in a research report on Monday, February 11th. Finally, BidaskClub upgraded Sientra from a “strong sell” rating to a “sell” rating in a research report on Thursday, April 25th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $21.00.

NASDAQ:SIEN opened at $6.70 on Wednesday. The company has a debt-to-equity ratio of 0.58, a current ratio of 1.52 and a quick ratio of 1.75. Sientra has a 1 year low of $6.44 and a 1 year high of $26.79. The firm has a market capitalization of $195.75 million, a price-to-earnings ratio of -2.06 and a beta of -0.10.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of Sientra in the fourth quarter valued at $29,000. BNP Paribas Arbitrage SA grew its position in shares of Sientra by 97,300.0% in the first quarter. BNP Paribas Arbitrage SA now owns 4,870 shares of the medical instruments supplier’s stock valued at $42,000 after purchasing an additional 4,865 shares in the last quarter. Great West Life Assurance Co. Can purchased a new position in shares of Sientra in the fourth quarter valued at $64,000. Commonwealth Equity Services LLC purchased a new position in shares of Sientra in the first quarter valued at $103,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Sientra by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 6,397 shares during the period. Institutional investors own 85.74% of the company’s stock.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Read More: Stock Symbol

Get a free copy of the Zacks research report on Sientra (SIEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.